Mongomery discusses SRX valuation, page-10

6186..there are trials and then there are trials. Generally speaking, with Biotechs the disasters have been with companies not making money seeking FDA or TGA approval, This is not the case, with SRX,...with SRX, a company already making great profits, the trials are more a marketing exerercise (ok somewhat oversimplifying things) to take the product to a new level of use (first line treatent). This makes SRX different. Apols if I am already posting the bleeding obvious. Yes poor results will impact greatly on SP, but will not destroy the co. As per most of biotechs seeking approval from FDA TGa.